Gender bias in clinical trials of biological agents for severe asthma: A systematic review

Abstract

Asthma is one of the most common chronic diseases characterized by sex disparities. Gender bias is a well-documented issue detected in the design of published clinical trials (CTs). International guidelines encourage researchers to analyze clinical data by sex, gender, or both where appropriate. The objective of this work was to evaluate gender bias in the published CTs of biological agents for the treatment of severe asthma. A systematic review of randomized controlled CTs of the biological agents (omalizumab, benralizumab, reslizumab, mepolizumab or dupilumab) for the treatment of severe asthma was conducted. The literature search was performed using PubMed and EMBASE without language restrictions. This study followed the corresponding international recommendations. We identified a total of 426 articles, of which 37 were finally included. Women represented 60.4% of patients included. The mean percentage of women in these trials was 59.9%, ranged from 40.8% to 76.7%. The separate analysis by sex of the main variable was only performed in 5 of the 37 publications included, and none of the trials analyzed secondary variables by sex. Only 1 of the articles discussed the results separately by sex. No study included the concept of gender in the text or analyzed the results separately by gender. The proportion of women included in CTs was higher compared to publications of other disciplines, where women were under-represented. The analysis of the main and secondary variables by sex or gender, even the discussion separately by sex, was insufficient. This gives rise to potential gender bias in these CTs.

Sex differences in adult asthma and COPD therapy: a systematic review

“…A first step to manage this important and discriminatory scientific lack could be to make the data from large investigational clinical trials in asthma and COPD available specifically for each sex rather than as overall results. Moreover, considering that clinical trials in asthma and COPD are characterized by imbalanced enrollment ratio between men and women leading to possible sex bias in measured outcomes [ 9 , 80 ], it is expected that the randomization procedures of future RCTs will be set to equally enroll both sexes. Finally, but not less important, pre-specified analyses in men and women should be planned in the trial protocols, a necessary condition that should be requested also by the regulatory agencies.…”

Big data- and machine learning-based analysis of a global pharmacovigilance database enables the discovery of sex-specific differences in the safety profile of dual IL4/IL13 blockade

“…In a study exploring sex bias in clinical trials in patients with severe asthma, studies involving omalizumab, benralizumab, reslizumab, mepolizumab and dupilumab in severe asthma was higher (60.4%) than the percentage of men. While sex bias in recruitment was not apparent, the separate analysis by sex of the main variable was carried out in only 5 of the 37 studies included, only 1 of the 37 trials discussed results separated by sex and no study included the concept of gender in the text (Ciudad-Gutiérrez et al, 2021).…”

Factors influencing poor response to type 2 targeted therapies in severe asthma: a retrospective cohort study

“…Therefore, gender bias in clinical trials of mabs in treating severe bronchial asthma is a concern; female is more presented. Nevertheless, men may receive more aggressive treatments despite women reporting worse symptoms than men, and the underrepresentation of men in trials may lead to biased outcomes (64)(65).…”